Nuveen
GYRE icon

Nuveen’s Gyre Therapeutics GYRE Stock Holding History

Nuveen’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
+24,505
New +$167K ﹤0.01% 3674
2025
Q3 		– Sell
-17,594
Closed -$129K – 3280
2025
Q2 		$129K Buy
+17,594
New +$154K ﹤0.01% 3233
2021
Q2 		– Sell
-14,777
Closed -$559K – 3447
2021
Q1 		$559K Buy
14,777
+4,091
+38% +$187K ﹤0.01% 3074
2020
Q4 		$505K Buy
10,686
+407
+4% +$17.6K ﹤0.01% 3042
2020
Q3 		$332K Hold
10,279
– – ﹤0.01% 3060
2020
Q2 		$453K Buy
+10,279
New +$483K ﹤0.01% 2939

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nuveen's GYRE Position: Q2 2026 in Review

Nuveen opened a new position in Gyre Therapeutics (GYRE) in Q2 2026: 24,505 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #3674 among its holdings. This is a return to the name: Nuveen previously reported a position in GYRE as recently as Q2 2025.

Nuveen first reported a position in GYRE in Q2 2020 and has held it in 6 quarters since. The position peaked at $559K in Q1 2021. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Nuveen held 24,505 shares of Gyre Therapeutics worth $161K as of Q2 2026.
  • Gyre Therapeutics was a new Nuveen position in Q2 2026.
  • Gyre Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3674 holding.
  • Nuveen first reported a position in Gyre Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • Nuveen's Gyre Therapeutics position peaked at $559K in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.